By Fineline Cube Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam Extended-Release Granules has received approval from China’s National Medical Products Administration (NMPA) for use as adjunctive therapy in the treatment of partial-onset seizures in epilepsy patients aged 12 years and older.
Regulatory Approval Overview
| Parameter | Detail |
|---|---|
| Regulatory Authority | China National Medical Products Administration (NMPA) |
| Product Classification | Category 2.2 modified drug (new formulation of existing active ingredient) |
| Approved Indication | Adjunctive therapy for partial-onset seizures in epilepsy patients ≥12 years |
| Company | Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) |
| Approval Date | 20 Jul 2026 |
| Market Exclusivity | First levetiracetam extended-release granule formulation approved in China |
Product Innovation & Clinical Advantages
- Active Ingredient: Levetiracetam – widely used antiepileptic medication with established safety profile in pediatric populations
- Novel Formulation: Extended-release granules designed specifically for pediatric patients and individuals with swallowing difficulties
- Key Differentiators vs. Existing Formulations:
- Superior to immediate-release tablets: Once-daily dosing improves compliance
- Superior to extended-release tablets: Granule format eliminates swallowing challenges
- Flexible administration: Can be mixed with food or liquid for easier ingestion
- Clinical Benefits: Enhanced medication adherence, consistent drug delivery, and improved quality of life for vulnerable patient populations
Target Patient Population Analysis
| Patient Segment | Current Challenges | Bio-Sincerity Solution |
|---|---|---|
| Pediatric Patients (12+ years) | Difficulty swallowing tablets; poor compliance with multiple daily doses | Granule formulation easily mixed with food; once-daily extended-release dosing |
| Patients with Dysphagia | Inability to safely swallow solid oral dosage forms | Granule format eliminates choking risk and swallowing discomfort |
| Non-compliant Patients | Complex dosing regimens leading to treatment gaps | Simplified once-daily administration improves adherence |
| Caregiver-Dependent Patients | Difficulty administering traditional formulations | Easy mixing with food/beverages simplifies caregiver burden |
Market Opportunity & Commercial Strategy
- Epilepsy Prevalence: China has an estimated 9 million epilepsy patients, with ~30% being pediatric cases
- Treatment Gap: Significant unmet need for age-appropriate, swallowing-friendly antiepileptic formulations
- Competitive Landscape: Levetiracetam market dominated by immediate-release and extended-release tablets; no granule formulations previously available in China
- Market Potential: Annual levetiracetam market in China exceeds ¥2 billion ($280 million), with premium pricing potential for innovative formulations
- Commercial Launch: Expected Q4 2026 through Bio-Sincerity’s established hospital and retail pharmacy distribution channels
- Reimbursement Strategy: Category 2.2 classification may qualify for favorable provincial reimbursement listing due to clear clinical advantages
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial prospects for Levetiracetam Extended-Release Granules. Actual results may differ due to risks including market adoption, competitive dynamics, and reimbursement decisions.-Fineline Info & Tech